SEC Filing Summary
Filing identity and period: The supplied filing is Sunshine Heart, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, filed March 20, 2015. It is not a Nuwellis, Inc. filing, and it reports annual results rather than standalone fourth-quarter results.
Business context
Sunshine Heart was an early-stage medical-device company developing the C-Pulse Heart Assist System for NYHA Class III and ambulatory Class IV heart-failure patients. The device was not approved for commercial sale in the United States; revenue came from clinical-study implants. The company held CE Mark approval in Europe but had not begun commercial sales there and was pursuing reimbursement and additional clinical evidence.
Financial results and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $295,000 | $59,000 |
| Operating expenses | $26.082 million | $22.930 million |
| Research and development expense | $16.874 million | $13.504 million |
| Selling, general and administrative expense | $9.208 million | $9.426 million |
| Operating loss | $25.787 million | $22.871 million |
| Net loss | $25.587 million | $21.758 million |
| Basic and diluted loss per share | $1.51 | $1.71 |
| Net cash used in operating activities | $22.644 million | $17.362 million |
| Cash and cash equivalents at year-end | $31.293 million | $54.136 million |
| Total liabilities at year-end | $3.158 million | $3.503 million |
Revenue remained very small and reflected five implants recognized in 2014 versus one in 2013. The company reported no debt on its December 31, 2014 balance sheet. After year-end, it entered a loan agreement for up to $10 million with Silicon Valley Bank: $6 million was funded at closing, with up to $4 million subject to milestones. The loan bears 7% annual interest and requires principal-and-interest repayment in 24 monthly installments beginning January 2016.
Cash fell by $22.843 million during 2014. The company also had $32.8 million remaining available under its at-the-market equity program as of March 16, 2015; it sold shares for net proceeds of $6.9 million from January 1 through February 27, 2015. Further equity financing could dilute shareholders.
Material changes and operating developments
- Revenue increased by $236,000, or 400%, from a low base. Net loss widened by $3.829 million.
- R&D expense rose 25%, primarily due to personnel and clinical-research infrastructure for U.S. and European studies. Management expected R&D spending to remain above prior-year levels during 2015.
- SG&A declined 2.3%, mainly because of lower stock-compensation costs; management expected these expenses to grow as the business expanded.
- Operating cash use increased by $5.282 million year over year, while cash and cash equivalents declined by $22.843 million.
- Accumulated deficit reached $126.6 million. The independent auditor stated that recurring losses and the accumulated deficit raised substantial doubt about the company’s ability to continue as a going concern.
Outlook, risks and unusual items
- Clinical and regulatory: COUNTER HF was designed to randomize 388 patients across up to 40 sites. It ended 2014 with 40 enrollments, 21 activated centers and 12 additional centers committed. In February 2015, FDA approved an interim analysis; in March 2015, enrollment was temporarily paused at a protocol-defined point. FDA requested an IDE supplement discussing the pause and resumption plan; the company submitted it March 16, 2015. The filing gives no clear final resumption date or trial outcome.
- Europe: OPTIONS HF, a post-market study intended to support clinical evidence and reimbursement, had completed 12 implants by year-end. The company did not expect German reimbursement before 2016 and could not predict whether or when reimbursement would be obtained in Germany or other target markets.
- Funding and going concern: The company expected significant future losses and said continued operations depended on raising capital and successfully developing and commercializing C-Pulse. The auditor’s going-concern warning makes financing availability and timing a material risk.
- Product and supply risks: Clinical experience was limited. Feasibility-study events included an aortic disruption, eight patients with driveline exit-site infections, and three patients rehospitalized for worsening heart failure by 12 months. The company also identified a single-source supplier for the specialized balloon component.
- Reimbursement and commercialization: U.S. clinical-study reimbursement was available at certain sites but not assured for every procedure; there was no European reimbursement approval. Commercial sales depended on regulatory approval, reimbursement, clinical results and the ability to build sales and manufacturing capacity.
- Other disclosures: No material pending legal proceedings or off-balance-sheet arrangements were reported. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not attest to internal-control effectiveness.
Key facts for investors to verify
- Confirm the issuer and reporting period: this source is Sunshine Heart, Inc.’s FY 2014 Form 10-K, not a Nuwellis filing or a standalone Q4 report.
- Review the latest clinical-trial and FDA updates, including the reason for the COUNTER HF pause, FDA feedback on the IDE supplement and current enrollment status.
- Assess cash burn, remaining ATM capacity, the terms and milestone availability of the bank loan, and the company’s ability to fund operations.
- Track U.S. approval requirements and European reimbursement progress, including whether any commercial sales or reimbursement approvals have occurred.
- Evaluate the clinical safety record, particularly infection and aortic-disruption risks, and the single-source balloon supply dependency.